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Abstract: Diffuse large B cell lymphoma (DLBCL) is a heterogenous disease that has been distinguished
into at least two major molecular entities, the germinal center-like B cell (GCB) DLBCL and
activated-like B cell (ABC) DLBCL, based on transcriptome expression profiling. A recurrent ch11q24.3
gain is observed in roughly a fourth of DLBCL cases resulting in the overexpression of two ETS
transcription factor family members, ETS1 and FLI1. Here, we knocked down ETS1 expression by
siRNA and analyzed expression changes integrating them with ChIP-seq data to identify genes
directly regulated by ETS1. ETS1 silencing affected expression of genes involved in B cell signaling
activation, B cell differentiation, cell cycle, and immune processes. Integration of RNA-Seq (RNA
sequencing) data and ChIP-Seq (chromatin immunoprecipitation sequencing) identified 97 genes
as bona fide, positively regulated direct targets of ETS1 in ABC-DLBCL. Among these was the
Fc receptor for IgM, FCMR (also known as FAIM3 or Toso), which showed higher expression in
ABC- than GCB-DLBCL clinical specimens. These findings show that ETS1 is contributing to the
lymphomagenesis in a subset of DLBCL and identifies FCMR as a novel target of ETS1, predominantly
expressed in ABC-DLBCL.
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1. Introduction
Diffuse large B cell lymphoma (DLBCL) constitutes the most common type of lymphoma,
accounting for 30–40% of new cases each year [1]. It is a heterogeneous diagnostic category with
diverse clinical, biological, and genetic presentations [1–6]. Based on transcriptional profiling, at least
two main subsets are distinguished based on their cell of origin, germinal center B cell (GCB)-like
DLBCL, and activated B cell (ABC)-like DLBCL [1–6], although a more subtle subdivision has been
more recently proposed, integrating transcriptional profiling, whole exome sequencing, and mutational
data [4–6]. Compared to GCB-DLBCL, ABC-DLBCL is associated with a poorer patient outcome
when treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP
(rituximab-CHOP) therapies and, phenotypically, resembles BCR-activated B cells arrested during
plasmacytic differentiation [1,2].
A ch11q24.3 region is recurrently gained in up to a fourth of DLBCL cases [7,8]. The gain is
associated with the overexpression of ETS1 and FLI1, two transcription factors belonging to the ETS
family of proteins [7]. The role of ETS1 has been well described in different malignancies of epithelial
tissues such as melanoma, breast cancer, and prostate cancer [9]. In healthy B cells, ETS1 is an important
regulator of development, differentiation, antibody production, and secretion [10–15]. In particular,
ETS1 mRNA is detected in pro-B, pre-B, and immature/mature B cells sorted from the bone marrow as
well as in mature splenic B cells, and downregulated in antibody secreting cells [10,15,16]. In mice,
the inhibition of Bcl6, Pax5, Mitf, Ets1, Fli1, and Spib gene expression are all involved in triggering
the switch into the plasma cell phenotype by directly or indirectly repressing BLIMP1 [17]. BLIMP1
is encoded by PRDM1 and is a master regulator of terminal B cell differentiation, often deleted or
disrupted in ABC-DLBCL [2,8]. Compared to GCB-DLBCL, ABC-DLBCL presents higher expression of
ETS1 [7], which is also more commonly phosphorylated at threonine (Thr) 38, as marker of ETS1 protein
activation [18]. We previously suggested that the gene might contribute to blocking the differentiation
toward plasma cells, for example, by inhibiting BLIMP1 [7]. Although the ch11q24.3 gain is not
associated with the ABC phenotype when DLBCL are split in the two main subtypes, an enrichment for
ch11q24.3 gains can be seen in the recently described DLBCL cluster 5, mainly comprising ABC-DLBCL,
and cluster 2, driven by TP53 inactivation [4]. These observations suggest that ETS1 can play a relevant
role in the transcriptional program of ABC-DLBCL. Thus, we studied the ETS1-regulated transcriptional
network by looking at the expression changes observed after gene silencing and integrating them with
ChIP-Seq data. Our data identify a role for ETS1 in the transcriptional network of ABC-DLBCL and
identify the putative Fc receptor for IgM, known as FAIM3/Toso, as a major gene target of ETS1.
2. Material and Methods
2.1. Cell Lines
Cell lines were cultured under standard conditions at 37 ◦C in a humidified atmosphere,
with 5% CO2. DLBCL cell lines of the ABC phenotype (U-2932, SU-DHL-2, OCI-Ly10, OCI-Ly3,
TMD8, HBL1) and GCB phenotype (SU-DHL-4, SU-DHL-6, FARAGE, VAL, KARPAS422, OCI-Ly1,
OCI-Ly8) were obtained and maintained as previously described [19,20], and their identity was
authenticated by short tandem repeat DNA profiling (IDEXX BioResearch, Ludwigsburg, Germany).
HEK293T cells used as packaging system for lentiviral production were cultured in Dulbecco’s
modified Eagle medium (DMEM) GlutaMax (Invitrogen, Carlsbad, CA, USA) supplemented with
25 mM D-Glucose, 1 mM Sodium pyruvate and 10% FBS.
2.2. Gene Silencing
For transient ETS1 knockdown we used the Amaxa 4D Nucleofector system (Lonza, Basel,
Switzerland) to introduce ON-TARGET SMARTpooled siRNA or a nontargeting siRNA as control
(Dharmacon GE Healthcare, Lafayette, CO, USA). Protocols were followed according to the SG Cell
Line 4D-Nucleofector X Kit L (Lonza). In brief, 2 × 106 cells were prepared and resuspended in
Cancers 2020, 12, 1912 3 of 17
100 µL SG solution with 500 nM siRNA or corresponding amounts of BLOCK-iT™ Alexa Fluor™ Red
Fluorescent Control (Invitrogen, Carlsbad, CA, USA) as a control for nucleofection efficiency. Efficiency
and cell viability were confirmed 48 h after nucleofection by flow cytometry and cells were harvested
for protein lysates and total RNA extraction.
Short hairpin RNAs were obtained from the Expression Arrest The RNAi Consortium (TRC)
library/Mission shRNA (short hairpin RNA) Library (Sigma-Aldrich, St. Louis, MO, USA). The shRNA
plasmids used were ETS1 shRNA plasmid TRCN0000005591 (sh60D) and FCMR shRNA plasmids
TRCN0000135954 (sh62C) and TRCN0000134014 (sh62D). All shRNA lentiviral plasmids were third
generation pLKO.1 vectors with puromycin resistance as a selection marker. For transient transfection
of HEK293T cells JetPrime (Polyplus Transfection), reagent was used. According to the manufacturer’s
protocol, 2.5 × 106 HEK293T cells were seeded on 100-mm plates with DMEM 24 h before transfection.
For each plate, a reaction mix was prepared with the necessary plasmids: pCMV-dR8.74 packaging
vector, pMD2.VSVG envelope vector and expression vector in a 1:1:5 ratio. The infection of target cells
was performed as previously described [7].
Cell viability was determined using Annexin V/PI assay, following manufacturer’s protocol.
Briefly, cells (2.5 × 105) were stained with 5 µL Annexin-V-FITC in 195 µL binding buffer (Thermo
Fisher Scientific, Waltham, MA, USA). Propidium iodide (PI) (Thermo Fisher Scientific, Waltham,
MA, USA) was added to samples before analysis by flow cytometry to discriminate early and late
stages of apoptosis. Acquisition of flow cytometry data was done using the BD FACSCanto system
(BD Bioscience, Allschwil, Switzerland) with the FACSDiva Software (eBioscience). Analysis of flow
cytometry data was done using FlowJo (Version, Treestar, City, State abbv. If USA/CA, Country).
2.3. RNA Extraction
RNA was isolated by Trizol (Invitrogen-Thermofisher, Waltham, MA, USA) and then DNAse was
treated using RNase-free DNase Kit (Qiagen, Germantown, MD, USA).
2.4. PCR Amplification and Quantitative Real-Time PCR
Total RNA extracts were reverse-transcribed using the SuperScript III First-strand Synthesis
SuperMix System kit (Invitrogen) to generate cDNA (complementary DNA). Then, 800 ng of total RNA
was mixed with RT Reaction Mix and RT Enzyme Mix, according to protocol. The qRT-PCR amplification
was performed using the KAPA SYBR FAST qPCR Master Mix (2×) ABI Prism™ on the StepOnePlus
Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). All primers were designed using the
web-based program Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi)
in combination with PrimerBlast for validation (https://www.ncbi.nlm.nih.gov/tools/primer-blast/).
The program run on the thermal cycler was: 95 ◦C for 3 s, 40 cycles with 95 ◦C 3 s/60 ◦C 30 s, followed
by dissociation step after denaturation and annealing. Primer efficiency was determined using linear
modelling for the amplification curves with the LinRegPCR software version 2015.4 [21]. Relative
quantification was calculated using the Pfaffl method [22]. Primers sequences are shown in Table S1.
2.5. Western Blotting
Cells were harvested and lysed by either boiling samples in 2× Laemmli sample buffer (BioRad,
Hercules, CA, USA) supplemented with β-mercaptoethanol (Merck, Kenilworth, NJ, USA) for 10 s
or according to manufacturer’s protocol using M-PER buffer (Thermo Fisher Scientific) with the
addition of HALT protease inhibitor cocktail (Thermo Fisher Scientific). Lysates (30–50 µg) were
resolved by electrophoresis using Mini-PROTEAN TGX Precast gels (4–20% gradient or 12%, BioRad).
After electrophoresis, the proteins were blotted to a nitrocellulose membrane (BioRad) by electric
transfer and the membranes were blocked in TBST (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1%
Tween 20) with 5% nonfat dry milk (BioRad) for 1 hr at room temperature.
The following primary antibodies were used in TBST 5% BSA (bovine serum albumin) buffer:
Rabbit polyclonal α-ETS1 (C-20, Santa Cruz, CA, USA), mouse monoclonal α-ETS1 (C-4, Santa Cruz,
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CA, USA), rabbit polyclonal α-pT38-ETS1 (ab59179, Abcam), mouse monoclonal α-Toso/FCMR (RR-16,
Santa Cruz), rabbit polyclonal α-AKT (Cell Signaling, Leiden, The Netherlands), rabbit polyclonal
α-pS473-pAKT (D9E, Cell Signaling), rabbit monoclonalα-IRF4 (D43H10, Cell Signaling). The following
primary antibodies were used in TBST 5% nonfat dry milk buffer: Mouse monoclonal α-GAPDH
(FF26A/F9, CNIO, Madrid, Spain). The secondary antibodies used were: ECL α-mouse IgG horseradish
peroxidase-linked species-specific whole antibody (GE Healthcare), ECL α-Rabbit IgG horseradish
peroxidase-linked species-specific whole antibody (GE Healthcare). Membranes were treated with
Westar ηC 2.0 chemiluminescent substrate (Cyanagen, Bologna, Italy) and signals were detected using
digital imaging with Fusion Solo (Vilber Lourmat, Witec AG, Sursee, Switzerland).
2.6. Transcriptome Analysis
RNA was extracted and processed for RNA-Seq (stranded, single-ended 75-bp-long sequencing
reads) using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England BioLabs
Inc., Ipswich, MA, USA) on a NextSeq 500 (Illumina, San Diego, CA, USA), as previously described [23].
Microarray-based gene expression profiling (GEP) was done with the Illumina Whole Genome Gene
Expression BeadChip, as previously described [7]. RNA-Seq was done starting from whole RNA
samples with the NEBNext rRNA Depletion kit, the NEBNext Ultra Directional RNA Library Prep Kit
for Illumina, and the NEBNext Multiplex Oligos for Illumina (New England BioLabs Inc.). Sequencing
was performed using a NextSeq 500 with the NextSeq 500/550 High Output Kit v2 (150 cycles
PE; Illumina).
2.7. Data Mining
Microarray data were analyzed as previously described [24]. RNA-Seq data mining was performed
as previously described [25]. For functional annotation [25], microarray data were processed with
regular gene set enrichment analysis while RNA-Seq data were processed with preranked GSEA (Gene
Set Enrichment Analysis) on fold change-ranked values, both using the default GSEA setting. Signatures
with nominal p-values < 0.05 and FDR < 0.1 were considered as biologically relevant. All expression
data will be available at the National Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) database. Publicly available expression profiles’
datasets of DLBCL clinical specimens obtained with Affymetrix Genechip U133 plus 2.0 [GSE10846 [3]
and GSE31312 [26]] and Affymetrix Human Genome U133A Array (GSE4475 [27] and GSE22470 [28])
were used. The CEL raw data files were imported and preprocessed by log2 transformation with
normalization using Bioconductor packages in R Studio (version 3.6). The GSE10846 dataset consisted
of two separate series of specimens, which were batch corrected. For dataset with available follow-up
data (GSE10846 and GSE31312), the median expression of FCMR was used as threshold to separate
high- and low-expression cases for the gene of interest. The log-rank test was used to investigate the
impact on overall survival of FCMR and the cumulative probability of OS (overall survival) was plotted
as a curve, according to the Kaplan–Meier method using R packages’ “survival” (version 3.1-12) and
“survminer” ( version 0.4.0). Multivariate analyses were performed using FCMR class (dichotomized
in high and low, median expression as cutoff) and cell of origin as covariates.
3. Results
3.1. Silencing Experiments Identify ETS1-Regulated Genes in ABC-DLBCL
To identify genes and pathways regulated by ETS1 in ABC-DLBCL, we performed microarray-based
gene expression profiling in three ABC-DLBCL cell lines (SU-DHL-2, OCI-Ly10, HBL1) after silencing
of the transcription factor using siRNA (Figures S1 and S2). Functional annotation showed higher
expression of transcripts involved in plasma cell differentiation, regulation of HIF1α targets, and genes
downregulated by BCR activation in the ETS1 knock-down samples compared to controls, indicating
negative regulation of these genes (Table 1 and Table S2). Conversely, the transcripts downregulated
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by siRNA and, thus, positively regulated by ETS1 were enriched in signatures related to BCR signaling,
CD40 signaling, NFκB/TNFα pathways, immune response, and early differentiation genes (Table 1 and
Table S2).
Table 1. Summary of GSEA results for microarray data comparing ETS1 knockdown versus control in
ABC-DLBCL cell lines.
Biological
Processes NAME NES FDR Source
B Cell Signaling
Pathways BASSO CD40 SIGNALING UP 2.28 <0.001 MSigDB
NFKB UP ALL OCILY3 LY10 2.11 0.002 SignatureDB
PID BCR 5PATHWAY 2.06 0.006 MSigDB
B CELL ACTIVATION 1.82 0.038 MSigDB
TIAN TNF SIGNALING VIA NFKB 1.80 0.039 MSigDB
PI3K OVEREXPRESSION UP 1.78 0.014 SignatureDB
ACTIVATION OF NF KAPPAB TRANSCRIPTION FACTOR 1.75 0.049 MSigDB
WIERENGA STAT5A TARGETS GROUP2 1.63 0.087 MSigDB
PI3K OVEREXPRESSION DOWN −1.53 0.070 Staudt
PID PI3KCI AKT PATHWAY −1.76 0.076 MSigDB
PID P38 MK2 PATHWAY −1.86 0.045 MSigDB
Cell Cycle REACTOME G2 M CHECKPOINTS 2.48 <0.001 MSigDB
HALLMARK E2F TARGETS 2.23 0.001 MSigDB
REACTOME S PHASE 2.01 0.010 MSigDB
B Cell
Differentiation MARSON FOXP3 TARGETS UP 2.33 <0.001 MSigDB
QI PLASMACYTOMA UP 2.29 <0.001 MSigDB
ZHAN EARLY DIFFERENTIATION GENES DN 2.26 0.001 MSigDB
PASQUALUCCI LYMPHOMA BY GC STAGE DN 2.12 0.003 MSigDB
POSITIVE REGULATION OF CELL DIFFERENTIATION 2.06 0.006 MSigDB
BLIMP BCELL REPRESSED 1.82 0.012 SignatureDB
REGULATION OF CELL DIFFERENTIATION 1.80 0.038 MSigDB
XBP1 TARGET ALL −1.75 0.030 SignatureDB
ZHAN LATE DIFFERENTIATION GENES UP −1.95 0.044 MSigDB
TARTE PLASMA CELL vs. B LYMPHOCYTE UP −2.11 0.016 MSigDB
PLASMACELL GENES INDUCED BYIRF4 SPIB −2.49 <0.001 CustomIOR
DLBCL Signatures DLBCL CLUSTER 4 FIG5 2.01 0.004 CustomIOR
IMMUNE DLBCL GENES 1.74 0.019 CustomIOR
GENES DOWNREGULATED AFTER IRF4 KNOCKDOWN
IN ABC DLBCL HBL1 1.60 0.037 CustomIOR
GENES UPREGULATED AFTER IRF4 KNOCKDOWN IN
ABC DLBCL HBL1 −1.68 0.024 CustomIOR
GENES UPREGULATED AFTER SPIB KNOCKDOWN IN
ABC DLBCL HBL1 −1.69 0.024 CustomIOR
IL6, IL10 STAT3 REGULATED GENES REPRESSED BY IRF4
SPIB −1.83 0.009 CustomIOR
Hypoxia HIF1ALPHA 2X DOWN 1.93 0.005 SignatureDB
WINTER HYPOXIA DN 1.77 0.044 MSigDB
Immune Processes IMMUNE RESPONSE 2.15 0.002 MSigDB
IMMUNE SYSTEM PROCESS 2.11 0.004 MSigDB
HUMORAL IMMUNE RESPONSE 1.79 0.041 MSigDB
PELLICCIOTTA HDAC IN ANTIGEN PRESENTATION UP −1.91 0.038 MSigDB
Myc Network KONG E2F3 TARGETS 2.31 <0.001 MSigDB
YU MYC TARGETS DN 1.97 0.013 MSigDB
ODONNELL TARGETS OF MYC AND TFRC DN 1.85 0.031 MSigDB
YU MYC TARGETS UP 1.78 0.041 MSigDB
E2F3 OVEREXPRESSION 2X UP 1.68 0.027 SignatureDB
CEBALLOS TARGETS OF TP53 AND MYC UP −1.81 0.062 MSigDB
The GSEA included four gene set collections (Hallmark, Curated gene sets, Gene Ontology) gene sets, Oncogenic
signatures) from the MSigDatabase, as well as Staudt Laboratory signatures and our own collection of custom
gene sets. Significant signatures with nominal p-value < 0.05 and FDR < 0.1, enriched in either the control, ETS1
expressing phenotype (positive NES values), or ETS1 knock-down phenotype (negative NES values), were considered
relevant. Signatures were manually grouped into biological processes. The used microarray data consisted of three
ABC-DLBCL cell lines with three biological replicates, each as controls and as ETS1 knock-down samples. NES =
normalized enrichment score; FDR = false discovery rate.
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To have a better insight of the transcripts regulated by ETS1, we studied two additional ABC-DLBCL
cell lines (TMD8 and U2932), this time performing RNA-Seq after ETS1 silencing by siRNA (Figure S3).
Functional annotation of the results largely confirmed the data obtained in the first three cell lines,
especially the ETS1 positive regulation of BCR signaling, CD40 signaling, NFκB/TNFα pathways,
immune response, and HIF1α responsive genes, and the negative effect on genes involved in plasma cell
differentiation (Table S3). In addition, we observed enrichment of genes involved in RNA processing
following ETS1 knockdown. At gene level, 224 transcripts were differently expressed (absolute log2
fold change≥0.2 and adj. (adjusted) p value < 0.05) (Figure S4, Table S3): 174 genes were downregulated
and, hence, positively regulated by ETS1 and 50 genes were upregulated following ETS1 silencing and,
hence, negatively regulated by ETS1. The differentially expressed genes with RNA-Seq included the
ETS1 positively regulated genes FCMR, RGS1, ARHGAP9, and SASH3, which were also observed in
the microarray analysis, and TNFAIP2, CTTN, and TNIP3 among the ETS1 negatively regulated genes
(Table 2 and Table S3). The CD52 and HCST genes were both identified in the microarray data and
were indeed expressed at lower levels after ETS1 knockdown in most cell lines, while downregulation
of RGS1 was moderate in most tested cell lines and only significant in HBL1. However, when we
validated by qRT-PCR, some of the genes, selected also based upon their potential relevance for DLBCL
biology [29–35], CD52, FCMR, RGS1, and HCST, were all confirmed as downregulated after ETS1
knockdown (Figure 1). In addition, we also evaluated the expression of the known negatively regulated
ETS1 target PRDM1 [7,36], coding for BLIMP1. Following ETS1 knockdown an upregulation of PRDM1
mRNA expression was observed in HBL-1 (Figure S5), one out of two cell lines bearing the PRDM1
gene in its wild-type configuration [8]. However, TMD8, the other cell line with wild-type PRDM1,
did not show any increase in expression, which could be due to insufficient knockdown of ETS1 for
this effect.
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Figure 1. Knockdown of ETS1 reduces the expression of genes with important functions in normal B 
cells and DLBCL cells. A qRT-PCR was used to determine the expression of the indicated genes 
following knockdown of ETS1 by siRNA in five ABC-DLBCL cell lines. The expression of each gene 
was normalized to GAPDH expression. Results shown are the average of three independent 
experiments; n = 3; error bars = standard deviation. Asterisk above bars indicates significant difference 
in expression, p < 0.05. 
The ETS1 regulation of these transcripts was further validated after silencing ETS1 using shRNA 
in TMD8 and HBL1 cells. A downregulation in mRNA expression was confirmed for all of them 
(CD52, FCMR, RGS1, and HCST), as well for other genes (PTPN7, ARHGAP9, SASH3, and GPSM3) 
that had been identified only in the RNA-Seq analysis (Figure S6). However, as not all genes were 
significantly reduced in the TMD8 cell line, this suggests that cell-type dependency and other factors 
could be involved in regulating these genes. 
Based on these data, ETS1 appears to control the expression of genes mainly involved in the B-
cell transcriptional program but also in RNA processing.  
Figure 1. Knockdown of ETS1 reduces the expression of genes with important functions in normal
B cells and DLBCL cells. A qRT-PCR was used to determine the expression of the indicated genes
following knockdown of ETS1 by siRNA in five ABC-DLBCL cell lines. The expression of each gene was
normalized to GAPDH expression. Results shown are the average of three independent experiments;
n = 3; error bars = standard deviation. Asterisk above bars indicates significant difference in expression.
The ETS1 regulation of these transcripts was further validated after silencing ETS1 using shRNA
in TMD8 and HBL1 cells. A downregulation in mRNA expression was confirmed for all of them (CD52,
FCMR, RGS1, and HCST), as well for other genes (PTPN7, ARHGAP9, SASH3, and GPSM3) that had
been identified only in the RNA-Seq analysis (Figure S6). However, as not all genes were significantly
reduced in the TMD8 cell line, this suggests that cell-type dependency and other factors could be
involved in regulating these ge es.
Based on these data, ETS1 appears to control the expression of genes mainly involved in the B-cell
transcriptional program but also in RNA processing.
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Table 2. Summary of preranked GSEA analysis of RNA-Seq data for ETS1 knockdown.
Biological Process Gene Set NES FDR Source
B Cell Signaling
Pathways MYD88 ALL DOWN 2.12 <0.001 SignatureDB
BASSO CD40 SIGNALING UP 1.91 0.008 MSigDB
PID RAS PATHWAY 1.90 0.009 MSigDB
PID IL2 STAT5 PATHWAY 1.82 0.018 MSigDB
SIG BCR SIGNALING PATHWAY 1.74 0.039 MSigDB
REACTOME ACTIVATION OF NF KAPPAB IN B CELLS −1.74 0.025 MSigDB
PI3K OVEREXPRESSION UP −2.03 0.001 SignatureDB
EGUCHI CELL CYCLE RB1 TARGETS −2.13 0.001 MSigDB
REACTOME CELL CYCLE −2.44 <0.001 MSigDB
REACTOME MEIOSIS −2.63 <0.001 MSigDB
B Cell
Differentiation MORI IMMATURE B LYMPHOCYTE UP 2.06 0.001 MSigDB
BLIMP BCELL REPRESSED 2.04 <0.001 SignatureDB
PAX5 REPRESSED 1.97 0.001 SignatureDB
MORI MATURE B LYMPHOCYTE UP 1.92 0.008 MSigDB
TARTE PLASMA CELL vs. B LYMPHOCYTE DN 1.66 0.064 MSigDB
PLASMACELL GENES INDUCED BYIRF4 SPIB −1.80 0.009 CustomIOR
MYELOMA TACI LOW PLASMABLAST GENE −1.85 0.005 SignatureDB
XBP1 TARGET SECRETORY −1.98 0.002 SignatureDB
MORI IMMATURE B LYMPHOCYTE DN −2.51 0.000 MSigDB
DLBCL Signatures IMMUNE DLBCL GENES 1.79 0.010 CustomIOR
GENES REPRESSED BYIRF4 SPIB GCB DLBCL 1.65 0.026 CustomIOR
Hypoxia HARRIS HYPOXIA 2.03 0.002 MSigDB
HIF1ALPHA 2X UP 1.79 0.009 SignatureDB
HIF1ALPHA 1.5X DOWN −3.04 <0.001 SignatureDB
MANALO HYPOXIA DN −3.10 <0.001 MSigDB
Immune processes KEGG CELL ADHESION MOLECULES CAMS 2.41 <0.001 MSigDB
IMMUNE RESPONSE 1.96 0.006 MSigDB
IMMUNE SYSTEM PROCESS 1.95 0.007 MSigDB
REACTOME INTEGRIN CELL SURFACE INTERACTIONS 1.84 0.015 MSigDB
RNA Processing
REACTOME MRNA SPLICING MINOR PATHWAY −1.98 0.003 MSigDB
KEGG SPLICEOSOME −2.04 0.002 MSigDB
REACTOME METABOLISM OF NON-CODING RNA −2.14 0.001 MSigDB
REACTOME MRNA SPLICING −2.16 0.001 MSigDB
REACTOME MRNA PROCESSING −2.24 0.000 MSigDB
Myc Network ODONNELL TARGETS OF MYC AND TFRC UP 2.11 0.001 MSigDB
MYC CHIP PET EXPR DOWN 1.90 0.002 SignatureDB
MYC RNAI OCILY3 −1.91 0.003 SignatureDB
HALLMARK MYC TARGETS V1 −2.70 <0.001 MSigDB
MYC OVEREXPRESSION 1.5X UP −2.96 <0.001 SignatureDB
Summary of GSEA result for RNA-seq data comparing ETS1 knockdown versus control in ABC-DLBCL cell lines.
The GSEA included four gene set collections (Hallmark, Curated gene sets, GO gene sets, Oncogenic signatures)
from the MSigDatabase, as well as Staudt Laboratory signatures and our own custom gene set collection signatures.
Control samples were compared to ETS1 siRNA-treated TMD8 and U2932. Significant signatures with nominal
p-value <0.05 and FDR < 0.1, enriched in either the ETS1 expressing phenotype (positive NES values) or ETS1
knockdown (negative NES values), were considered relevant. Signatures were manually grouped into biological
processes. The used RNA-seq data consisted of two ABC-DLBCL cell lines with three biological replicates each as
controls and as ETS1 knockdown. NES = normalized enrichment score, FDR = false discover rate.
3.2. Integration with ChIP-Seq Data Identifies Putative Direct ETS1 Targets and Their Overlap with BCL6,
BLIMP1, and PAX5 Targets
To identify direct targets of ETS1, we took advantage of the ChIP-Seq data available at Cistrome
database [37]. A list of 6760 putative ETS1 gene targets identified in human B cell lymphoblasts
(Accession number GSM803510 [38]) were overlapped with the list of 224 transcripts from our
RNA-Seq data. Ninety-seven genes that were identified as positively regulated by ETS1 following
ETS1 knockdown, overlapped with putative ETS1 targets identified by ChIP-Seq (Figure 2A, Table S3).
An overlap with putative ETS1 targets was also found for 12 of the genes we identified as negatively
regulated by ETS1 (Figure 2A, Table S3). The above mentioned ARHGAP9, FCMR, SASH3, and RGS1
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were among the positively regulated. To include our microarray data in this analysis, we generated a
signature of the genes that were overlapping and performed a GSEA (Figure 2B). Figure S7 shows
ETS1 binding sites in four different genes (HCST, FCMR, SASH3, and CD79A) as examples.
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Exploiting three additional ChiP-Seq datasets (GSM1668937 [39], GSM2735456 [40], GSM803334 
[38]), we identified direct ETS1 targets that overlap with genes regulated by BCL6, BLIMP1, and 
PAX5, three transcription factors that are also important for normal and neoplastic B cells (Figure 3; 
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Figure 2. Direct ETS1 targets identified in gene expression profiling data for ABC-DLBCL cell lines with
or without ETS1 knockdown. (A) Overlap of significant ETS1 upregulated or downregulated genes,
identified from RNA-Seq data of CTR siRNA compared to ETS1 siRNA-treated TMD8 and U-2932 cell
lines, with putative ETS1 targets from the publicly available Chip-Seq dataset GSM803510 obtained
from B lymphoblasts. (B) Heatmap showing the GEP profile data (HBL1, OCI-Ly10, SU-DHL-2) for
the top featured genes in the gene set for ETS1 positively regulated direct target genes identified in
the RNA-Seq and ChIP-seq overlap. Expression values in the heatmap (high, moderate, low, lowest)
are represented by a color range (red, pink, light blue, dark blue). In the GSEA plot: Green curve,
enrichment score; bars in the middle portion of the plots show where the members of the gene set
appear in the ranked list of genes; positive or negative ranking metric indicates, respectively, correlation
or inverse correlation with the profile; NES, normalized enrichment score; FDR, false discovery rate.
Exploiting three additional ChiP-Seq datasets (GSM1668937 [39], GSM2735456 [40], GSM803334 [38]),
we identified direct ETS1 targets that overlap with genes regulated by BCL6, BLIMP1, and PAX5,
three transcription factors that are also important for normal a d neoplastic B cells (Figure 3; Table S3).
Among th 97 positively regulated direct ETS1 targets, the greatest overlap was with PAX5 ta gets
(80%), followed by BCL6 (49%): 41% of the 97 ETS1 targets were targeted by both PAX5 and BCL6.
Conversely, there was only 24% overlap with BLIMP1 targets. The genes apparently co-regulated
by ETS1, PAX5, and BCL6 comprised FCMR, CD40, CD79A, LMO2, PDE4A, CIITA, and IL16 among
others. The overlap with PAX5 targets (83%) was the highest also among the 12 negatively regulated
targets. These findings suggest that ETS1 directly participates in the transcriptional network regulated
by BCL6, and PAX5 and BLIMP1.
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TMD8 and U2932 ABC-DLBCL cell lines.
3.3. The Novel ETS1 Target FCMR Is Mainly Expressed in ABC-DLBCL
The gene FCMR, also known as TOSO or FAIM3, was among the most downregulated genes
after ETS1 silencing and presented ETS1 binding at its promoter, suggesting that FCMR is a putative
direct target of ETS1. FCMR, initially described to code for an inhibitor of FAS-mediated apoptosis in
T cells [41], is now recognized as coding for the Fc receptor for IgM [32,42].
ABC-DLBCL cells predominantly express IgM isotype antibodies [43], suggesting that autocrine
FCMR signaling may contribute to tumorigenesis in lymphomas with ETS1-driven FCMR upregulation.
Therefore, we decided to investigate FCMR expression more closely in cell lines and clinical specimens.
We demonstrated that the protein was detected in cell lines derived from ABC-DLBCL (n = 6)
while no expression was seen in GCB-DLBCL (n = 7) cell lines (p = 0.009, Figure 4A). Levels of
FCMR mRNA levels were also higher in ABC-DLBCL than in GCB-DLBCL cell lines (p = 0.045,
Figure 4B). In accordance with this observation, FCMR expression was always higher in ABC- than in
GCB-DLBCL (p < 0.001) across different series of DLBCL clinical specimens (GSE10846 [3], GSE4475 [27],
GSE22470 [28], and GSE31312 [26]) (Figure 4C). Similarly, ETS1 expression was significantly higher
in ABC-DLBCL in the same datasets (Figure 4D). A high FCMR expression was associated with
an inferior outcome in DLBCL patients, as assessed using two available datasets (GSE10846 [3],
GSE4475 [27]). However, in agreement with the higher levels of FCMR in ABC- than GCB-DLBCL,
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it was not independent from the cell of origin at multivariate analyses, as also shown by the survival
curves in the individual ABC or GCB subtypes (Figure S8).
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Figure 4. FCMR expression in clinical specimens and DLBCL cell lines. (A) Protein expression of
FCMR in seven GCB-DLBCL and six ABC-DLBCL cell lines. FCMR (FAIM3) protein expression was
significantly associated with ABC-DLBCL cell lines (Chi-square p = 0.009). IRF4 expression was only
expected in ABC-DLBCL cell lines. The α-GAPDH was used as loading control, n = 3. (B) Quantitative
real-time PCR analysis of FCMR expression in seven GCB-DLBCL and six ABC-DLBCL cell lines. Solid
white lines in box-plots represent the median FCMR expression per each subset. (C,D) Differential
expression of FCMR or ETS1 in four datasets comparing GCB-DLBCL to ABC-DLBCL. Expression
values are Log2 transformed. Significance calculated with the Wilcoxon rank sum test. Uncropped
blots See Figure S9.
Since FCMR can have a modulatory effect on BCR signaling pathways [33,44,45], to see whether
FCMR expression has any relevance for BCR signaling in ABC-DLBCL, we knocked down FCMR
expression in two cell lines (TMD8 and HBL1) with two separate shRNAs (sh62C and sh62D) (Figure 5A).
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We saw a decrease in the levels of phosphorylation in pETS1 and pAKT(Ser473) in FCMR knock-down
samples (Figure 5B) and there were significant differences in proliferation (but not in cell viability) in
FCMR knock-down cells compared to control, if maintained in normal cell culture (Figure 5C).
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4. Discussion
We presented a full investigation of networks regulated by the ETS1 transcription factor in
ABC-DLBCL, performing transcriptome profiling after gene silencing, followed by functional annotation
and integration with Chip-Seq data.
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ETS1 appeared to regulate important biologic pathways: BCR activation, B cell differentiation,
proliferation, and antiapoptotic pathways. These features can all be related to the main phenotype
of ABC-DLBCL (constitutive B cell activation, block of terminal differentiation), indicating that ETS1
contributes to the molecular pathogenesis of this subset. The effect was largely due to a direct
regulation of genes involved in these pathways, as shown by their identification as true bona fide ETS1
direct targets.
Among the ETS1 positively regulated targets there were CD79A, ARHGAP9, GPSM3, PTPN7,
SASH3, HCST, RGS1, CD52, and FCMR, which are part of signaling pathways known to promote B
cell proliferation and survival. Together with PAX5, ETS1 interacts with the mouse mb-1 promoter
coding for CD79 [46]. Accordingly, we observed both CD79A downregulation after ETS1 knockdown
as well as ETS1 enrichment at the gene promoter in publicly available ChIP-seq data. Interestingly,
gain-of-function mutations affecting ITAM subunits of CD79A/B are observed in up to 20% of DLBCL
patients [2,4–6]. Our findings, therefore, raise the possibility that ETS1 amplifies the tumor-promoting
effects of these mutants by increasing their expression and, indeed, ETS1 gains are common in the
ABC-DLBCL cluster 5 characterized by MYD88 and CD79A/B [4].
ARHGAP9 codes for a Rho GTPase, playing a role in adhesion processes of hematopoietic cells to
extracellular matrix, including an inhibitory activity on MAPK signaling [47]. Due to the connection
between MAP kinase cascade and ETS1 activity, this could be part of a negative feedback loop and also
indicates that ETS1 might have a role in tumor cells’ migration. RGS1 is a member of the regulator of
G protein-signaling family, expressed in GC B cells and lymphoma cell lines in which it desensitizes
cells to chemoattractant, localizing cells to the lymph node [29]. RGS1 expression also correlates with
ABC-DLBCL and with poor prognosis [30]. CD52 is a glycoprotein expressed on T and B cells, with a
still-unclear function. CD52 is expressed in 75% of DLBCL cases and is downregulated in plasma
cells. CD52 is also the target of the monoclonal antibody alemtuzumab that has shown low anti-tumor
activity in DLBCL patients based on a series of 11 relapsed or refractory cases, not characterized for
CD52 expression [31]. HCST is an adaptor protein initially described in NK cells and T cells, which,
once phosphorylated, becomes a docking site for PI3K [34,35]. GPMS3 is a protein that regulates
downstream intracellular signals initiated by G protein-coupled receptors and is involved in regulation
of chemoattractant-mediated migration [48]. PTPN7 is a protein tyrosine phosphatase known to
dephosphorylate MAPKs in hematopoietic cells, deregulated via amplifications in leukemias but
deletions in lymphomas [49]. The fact that this gene is downregulated after ETS1 knockdown could
suggest that PTPN7 is a target involved in a negative feedback loop for ETS1 expression. ERK-mediated
ETS1 phosphorylation can lead to increased ETS1 expression via p38 MAPK [11,12,50,51]. This pathway
could potentially be inhibited by PTPN7 expression induced by ETS1. Finally, SASH3, reported to be
expressed in T and B cell lymphoma cell lines, is involved in signal transduction affecting immune
system development and immune response [52].
As already mentioned, other transcription factors important for normal and neoplastic B cells
are BCL6, BLIMP1, and PAX5. The integration of ETS1 data with publicly available ChiP-Seq
datasets [38–40] indicates that there is a high overlap of the ETS1 transcriptional network with genes
regulated by these other three transcriptional factors, and especially with PAX5. This is in strong
agreement with the notion that ETS1 and PAX5 closely interact at the DNA level to perform their
regulatory activity [46,53,54]. Differently from GCB-DLBCL, ABC-DLBCL most commonly express
the IgM isotype, attributed to a genetic disruption of the switch µ region at the IgH locus, preventing
Ig class switching [43,55]. The IgM phenotype also favors block of terminal differentiation unlike
the IgG expression [33]. This notion led us to select FCMR for further investigation. The FCMR
gene codes for an immunoglobulin receptor that is highly selective for IgM and can contribute to
B cell activation [32,33]. However, the biologic role of FCMR in both normal and neoplastic B cells
has not been fully understood [56]. Mouse models have shown that FCMR knock-down B cells
have increased germinal center formation and reduced class switch and generation of Ag-specific
plasma cells [45,57]. Although in CLL FCMR is overexpressed and associated with a more aggressive
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disease [58], in the Eµ-TCL1 transgenic CLL mouse model, FCMR loss confers an aggressive phenotype
with transformation to DLBCL [59]. We observed that FCMR-silenced ABC-DLBCL cells present
lower levels of phospho-ETS1 and phospho-AKT (Ser 473) compared to control cells. These data
would suggest an important role of FCMR on ABC-DLBCL signaling (in AKT/ETS1 pathway).
Indeed, FCMR-silenced ABC-DLBCL cells present a lower/slower growth curve compared to control
cells. Our results demonstrated an important role for ETS1 in the direct regulation of FCMR, which,
in turn, creates a positive loop with the upregulation of pETS1 and pAKT. These data would suggest a
positive regulation by FCMR on ABC-DLBCL signaling, data fitting with the reported reduced tonic
BCR signaling in FCMR-deficient mice [60]. However, the definition of the role of FCMR in normal
and malignant B cells, especially in ABC-DLBCL, will need further studies [56].
5. Conclusions
Our study showed that ETS1 regulates pathways that are fundamental for ABC-DLBCL, indicating
that the gene contributes to the pathogenesis of this lymphoma subtype. Among ETS1 direct targets,
we identified FCMR, which was significantly more expressed in ABC-DLBCL than GCB-DLBCL and
contributes to an increased cell growth with an upregulation of pETS1 and pAKT.
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